This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Olympus, Republic Wireless: Hot Trends

Stocks in this article: PFE

NEW YORK ( TheStreet) -- Popular searches on the Internet Tuesday include Olympus after the Japanese company said three executives, including its former chairman, helped conceal decades of losses.

Olympus said former Chairman Tsuyoshi Kikukawa, Executive Vice President Hisashi Mori and auditor Hideo Yamada took part in the cover-up by paying inflated fees to takeover advisers in effort to hide the losses. This comes after weeks of accusations against the company regarding its purchase of Gyrus Group in 2008 and three other takeovers. The company had continuously denied any allegations of wrongdoing.

Now, regulators are investigating allegations that Olympus, the camera and medical equipment maker, siphoned more than $1 billion through offshore accounts. The Tokyo Stock Exchange said it is contemplating moving Olympus shares to a watch list for a possible delisting.

Another hot search Tuesday is Republic Wireless as the startup company has launched a limited beta version of its $19-a-month wireless service.

For now, the service will be available on the LG Optimus smartphone. Republic Wireless will take on Sprint Nextel (S) as its first cellular partner in the agreement, in which the smartphone and one month of service will go for $199, with unlimited voice, data and texting costing $19 a month afterward.

Republic Wireless is calling the service "the world's first $19-a-month hybrid calling plan," while leaving the window open for future price drops even further. The phone will connect with Wi-Fi first, but when Wi-Fi is unavailable the connection will switch over to the cellular network. The company said the price could drop below $19 a month if customers use Wi-Fi a great deal.

Customers won't have to sign a contract, and the company said there will be no overage fees.

Cholesterol drug also is trending as the patent on Pfizer's (PFE) Lipitor is about to expire.

The cash cow drug has reached $130 billion in sales since its creation in 1997. When its patent expires on Nov. 30, a slew of cheap generic forms of the drug are anticipated to hit the market. Without patent protection, any generic drug company will be able to create cheaper versions of Lipitor. Now, in a possible attempt to stay competitive, Pfizer itself is saying it could be one of companies to introduce a generic version of the cholesterol fighter.

The drug lowers levels of "bad" LDL cholesterol, cutting the risk of heart attack and stroke.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs